Literature DB >> 14744808

Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs.

Orsolya Nagy1, Agnes Hajnal, James R Parratt, Agnes Végh.   

Abstract

Sildenafil (Viagra) prolongs repolarisation in cardiac muscle, an effect that could lead to ventricular fibrillation (VF). Sildenafil (2 mg kg(-1)) was given by mouth to 12 mongrel dogs and, 24 h later, these dogs were anaesthetised, thoracotomised and subjected to a 25 min occlusion of the anterior descending coronary artery. Haemodynamic parameters were similar in this and the control group, but there were fewer and less serious ventricular arrhythmias during occlusion in the sildenafil group (VF 17 vs 60%; ventricular premature beats 140+/-52 vs 437+/-127% and episodes of ventricular tachycardia 4.0+/-3.2 vs 19.3+/-7.7%, all P<0.05). However, reperfusion VF and indices of ischaemia severity (epicardial ST-segment mapping, inhomogeneity) were not modified by the drug. Sildenafil increased the QT interval, especially during ischaemia. Our conclusion is that ischaemia-induced ventricular arrhythmias are reduced by sildenafil, but this protection is less pronounced than that following cardiac pacing or exercise.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744808      PMCID: PMC1574240          DOI: 10.1038/sj.bjp.0705658

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  The local intracoronary administration of methylene blue prevents the pronounced antiarrhythmic effect of ischaemic preconditioning.

Authors:  A Vegh; J G Papp; L Szekeres; J Parratt
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

2.  Pacing-induced delayed protection against arrhythmias is attenuated by aminoguanidine, an inhibitor of nitric oxide synthase.

Authors:  A Kis; A Végh; J Papp; J Parratt
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

3.  Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis.

Authors:  K Przyklenk; R A Kloner
Journal:  J Am Coll Cardiol       Date:  2001-01       Impact factor: 24.094

Review 4.  The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5.

Authors:  R M Wallis
Journal:  Nihon Yakurigaku Zasshi       Date:  1999-10

5.  Delayed cardioprotective effects of exercise in dogs are aminoguanidine sensitive: possible involvement of nitric oxide.

Authors:  László Babai; Zsolt Szigeti; James R Parratt; Agnes Végh
Journal:  Clin Sci (Lond)       Date:  2002-04       Impact factor: 6.124

Review 6.  Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.

Authors:  Ursula Gresser; C H Gleiter
Journal:  Eur J Med Res       Date:  2002-10-29       Impact factor: 2.175

7.  Role of cyclic guanosine monophosphate in late preconditioning in conscious rabbits.

Authors:  Eitaro Kodani; Yu-Ting Xuan; Hitoshi Takano; Ken Shinmura; Xian-Liang Tang; Roberto Bolli
Journal:  Circulation       Date:  2002-06-25       Impact factor: 29.690

8.  Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits.

Authors:  Ramzi Ockaili; Fadi Salloum; John Hawkins; Rakesh C Kukreja
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-09       Impact factor: 4.733

9.  Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart.

Authors:  Fadi Salloum; Chang Yin; Lei Xi; Rakesh C Kukreja
Journal:  Circ Res       Date:  2003-03-13       Impact factor: 17.367

10.  Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats.

Authors:  A Vegh; S Komori; L Szekeres; J R Parratt
Journal:  Cardiovasc Res       Date:  1992-05       Impact factor: 10.787

View more
  14 in total

1.  Antiarrhythmic drug research.

Authors:  M J A Walker
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 2.  Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.

Authors:  Sevil Korkmaz-Icöz; Tamás Radovits; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

3.  Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.

Authors:  R C Kukreja
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

Review 4.  Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?

Authors:  R Pofi; D Gianfrilli; R Badagliacca; C Di Dato; M A Venneri; E Giannetta
Journal:  J Endocrinol Invest       Date:  2015-07-05       Impact factor: 4.256

5.  Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.

Authors:  Rakesh C Kukreja; Fadi N Salloum; Anindita Das; Saisudha Koka; Ramzi A Ockaili; Lei Xi
Journal:  Exp Clin Cardiol       Date:  2011

Review 6.  Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety.

Authors:  Sumon Roy; Robert A Kloner; Fadi N Salloum; Ion S Jovin
Journal:  Cardiovasc Drugs Ther       Date:  2021-10-15       Impact factor: 3.947

Review 7.  Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.

Authors:  Yuan James Rao; Lei Xi
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

8.  Preventive effect of sildenafil on right ventricular function in rats with monocrotaline-induced pulmonary arterial hypertension.

Authors:  Rieko Yoshiyuki; Ryo Tanaka; Ryuji Fukushima; Noboru Machida
Journal:  Exp Anim       Date:  2016-02-12

9.  Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy.

Authors:  Luigi Di Luigi; Clarissa Corinaldesi; Marta Colletti; Sabino Scolletta; Cristina Antinozzi; Gabriella B Vannelli; Elisa Giannetta; Daniele Gianfrilli; Andrea M Isidori; Silvia Migliaccio; Noemi Poerio; Maurizio Fraziano; Andrea Lenzi; Clara Crescioli
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

10.  Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.

Authors:  Simon G Anderson; David C Hutchings; Mark Woodward; Kazem Rahimi; Martin K Rutter; Mike Kirby; Geoff Hackett; Andrew W Trafford; Adrian H Heald
Journal:  Heart       Date:  2016-07-26       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.